Having previously worked in the European chemicals industry, Dave has been with Generics Bulletin since 2010. Keeping a close eye on deals, corporate strategy and market developments in the off-patent sector, he also brings his background and education in law to bear on industry litigation as well as national legislative and regulatory affairs, with a particular interest in France where he has lived and studied in the past. A regular delegate to generics and biosimilars events and conferences as well as a frequent panel moderator, he maintains close links with industry representatives around the world. He also organizes and judges the annual Global Generics & Biosimilars Awards. In his spare time, he enjoys art and playing the piano.
Latest From David Wallace
Building A US Business: Celltrion’s New CCO Talks Strategy
With Celltrion transitioning to a direct sales model in the US after previously partnering with other firms to market its biosimilars, the company’s new US chief commercial officer, Tom Nusbickel, talks to Generics Bulletin about how the firm is gearing up to launch three key products.
Trio Of Hikma Launches Includes New Icosapent Strength
Hikma has launched three new generics in quick succession, including a new strength of its icosapent ethyl capsules that rival Vascepa, as well as unique presentations of its cefazolin and labetalol injectables.
Samsung Bioepis Reveals Ustekinumab Progress
Samsung Bioepis has reported positive Phase I data for its SB17 ustekinumab candidate, a proposed biosimilar to Stelara.
‘In A Word, Complicated’ – AAM’s Burton Talks US Biosimilars
With the first US Humira rival having just hit the market and biosimilars seeing increasing adoption overall, Craig Burton – executive director of the AAM’s Biosimilars Council – says that the US biosimilars market is ‘doing better, but we still have improvements to make.’
Sandoz Gains An Edge With High-Concentration US Humira Biosimilar
Sandoz has gained a potential advantage ahead of being part of a second wave of Humira biosimilar competition hitting the US, with the firm obtaining FDA approval for its Hyrimoz version of adalimumab in a citrate-free high-concentration formulation.
AAM Departures Lead To Change Of Chair For IGBA
The AAM has confirmed the departure of three executives, one of whom had also been serving as chair of the IGBA. As a result, the global generics industry association has brought in a new interim chair, at the same time as the head of one of the industry’s largest players has joined its CEO Advisory Committee.